Ilyang Pharmaceutical Co.,Ltd (007575) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.026x

Based on the latest financial reports, Ilyang Pharmaceutical Co.,Ltd (007575) has a cash flow conversion efficiency ratio of -0.026x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-6.76 Billion ≈ $-4.58 Million USD) by net assets (₩256.94 Billion ≈ $174.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ilyang Pharmaceutical Co.,Ltd market cap and net worth for the company's overall valuation and market capitalisation.

Ilyang Pharmaceutical Co.,Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Ilyang Pharmaceutical Co.,Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Ilyang Pharmaceutical Co.,Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ilyang Pharmaceutical Co.,Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Ilyang Pharmaceutical Co.,Ltd to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
ITEK Inc KQ:119830	0.034x
Ubiquoss Holdings Inc KQ:078070	0.055x
Freeman Gold Corp V:FMAN	-0.019x
FG Merger II Corp. Unit NASDAQ:FGMCU	0.002x
JAKS Resources Bhd KLSE:4723	-0.007x
Western Asset Investment Grade Defined Opportunity Closed Fund NYSE:IGI	N/A
Cardiff Oncology Inc NASDAQ:CRDF	-0.131x
Maronan Metals Ltd AU:MMA	-0.179x

Annual Cash Flow Conversion Efficiency for Ilyang Pharmaceutical Co.,Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Ilyang Pharmaceutical Co.,Ltd from 2014 to 2025. View 007575 stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩241.41 Billion ≈ $163.60 Million	₩12.04 Billion ≈ $8.16 Million	0.050x	+112.78%
2024-12-31	₩239.53 Billion ≈ $162.33 Million	₩5.61 Billion ≈ $3.81 Million	0.023x	-68.51%
2023-12-31	₩196.41 Billion ≈ $133.10 Million	₩14.62 Billion ≈ $9.91 Million	0.074x	-27.43%
2022-12-31	₩291.85 Billion ≈ $197.79 Million	₩29.94 Billion ≈ $20.29 Million	0.103x	-58.41%
2021-12-31	₩271.76 Billion ≈ $184.17 Million	₩67.02 Billion ≈ $45.42 Million	0.247x	+5.08%
2020-12-31	₩244.92 Billion ≈ $165.98 Million	₩57.48 Billion ≈ $38.96 Million	0.235x	+44.44%
2019-12-31	₩222.74 Billion ≈ $150.95 Million	₩36.19 Billion ≈ $24.53 Million	0.162x	+54.17%
2018-12-31	₩209.88 Billion ≈ $142.23 Million	₩22.12 Billion ≈ $14.99 Million	0.105x	-25.94%
2017-12-31	₩210.98 Billion ≈ $142.98 Million	₩30.03 Billion ≈ $20.35 Million	0.142x	+14.64%
2016-12-31	₩217.35 Billion ≈ $147.30 Million	₩26.98 Billion ≈ $18.29 Million	0.124x	-34.96%
2015-12-31	₩211.00 Billion ≈ $142.99 Million	₩40.27 Billion ≈ $27.29 Million	0.191x	+87.97%
2014-12-31	₩183.46 Billion ≈ $124.33 Million	₩18.63 Billion ≈ $12.62 Million	0.102x	--

About Ilyang Pharmaceutical Co.,Ltd

KO:007575 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$92.33 Million

₩136.24 Billion KRW

Market Cap Rank

#19573 Global

#993 in Korea

Share Price

₩7500.00

Change (1 day)

+0.94%

52-Week Range

₩7000.00 - ₩12980.00

All Time High

₩141909.13